Efficacy and safety of adding evogliptin versus sitagliptin for metformin-treated patients with type 2 diabetes: A 24-week randomized, controlled trial with open label extension-Reference-Cited by-同舟云学术

Efficacy and safety of adding evogliptin versus sitagliptin for metformin-treated patients with type 2 diabetes: A 24-week randomized, controlled trial with open label extension

Published:2017-02-22 Issue:5 Volume:19 Page:654-663
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Hong Sang-Mo¹^ORCID,Park Cheol-Young²,Hwang Dong-Min³,Han Kyung Ah⁴,Lee Chang Beom⁵,Chung Choon Hee⁶,Yoon Kun-Ho⁷,Mok Ji-Oh⁸,Park Kyong Soo⁹,Park Sung-Woo²

Affiliation:

1. Department of Internal Medicine; Hallym University Dongtan Sacred Heart Hospital; Hwaseong-si Republic of Korea

2. Department of Internal Medicine, Kangbuk Samsung Hospital; Sungkyunkwan University School of Medicine; Seoul Republic of Korea

3. Data Management and Clinical Statistics Team, Dong-A ST; Seoul Republic of Korea

4. Department of Internal Medicine; Eulji University College of Medicine; Daejeon, Republic of Korea

5. Department of Internal Medicine, College of Medicine; Hanyang University; Seoul Republic of Korea

6. Department of Internal Medicine; Yonsei University Wonju College of Medicine; Wonju Republic of Korea

7. Department of Internal Medicine, College of Medicine; The Catholic University of Korea; Seoul South Korea

8. Department of Internal Medicine; Soonchunhyang University College of Medicine; Bucheon-si Republic of Korea

9. Department of Internal Medicine, College of Medicine; Seoul National University; Seoul Republic of Korea

Funder

Dong-A ST Co., Ltd

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12870/fullpdf

Reference27 articles.

1. Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas;Deacon;Diabetes Obes Metab,2016

2. American Diabetes Association. Approaches to glycemic treatment;Diabetes Care,2016

3. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2016 executive summary;Garber;Endocr Pract,2016

4. Clinical decisions. Management of type 2 diabetes--polling results;Schulte;N Engl J Med,2014

5. Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers;Gu;Drug Des Devel Ther,2014

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular safety of evogliptin dual and triple therapy in patients with type 2 diabetes: a nationwide cohort study;BMJ Open;2024-04

2. Pharmacokinetic and pharmacodynamic drug–drug interactions between evogliptin and empagliflozin or dapagliflozin in healthy male volunteers;Clinical and Translational Science;2023-06-21

3. The efficacy and safety of evogliptin for type 2 diabetes mellitus: A systematic review and meta-analysis;Frontiers in Endocrinology;2022-08-19

4. A double‐blind, Randomized controlled trial on glucose‐lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase‐4 inhibitor therapy: REFIND study;Diabetes, Obesity and Metabolism;2022-06-09

5. Evogliptin for the treatment option for type 2 diabetes: an update of the literature;Expert Review of Clinical Pharmacology;2022-06-03